Fujifilm to make Toyama Chemical subsidiary via tender offer

Fujifilm to make Toyama Chemical subsidiary via tender offer

TOKYO, Japan - Fujifilm Holdings Corp. President Shigetaka Komori, Taisho Pharmaceutical Co. President Akira Uehara and Toyama Chemical Co. President Masuji Sugata (L to R) shake hands Feb. 13 after attending a news conference in Tokyo where Fujifilm said it will launch a friendly tender offer for shares in Toyama Chemical and turn the drug maker into a subsidiary. Fujifilm will acquire 66.7 percent of Toyama while Taisho, Toyama's current top shareholder with a 21.8 percent stake, will raise its stake by acquiring an additional 14.93 million Toyama shares.

  • Product Code
  • ILEA001126061
  • Registered date
  • 2008/2/13 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2008 Kyodo News
  • Media size
  • 1864 × 1228 pixel
  • Resolution
  • dpi
  • Deployment size
  • 446.37(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Replacement of Daihatsu Motor president

    Replacement of Daihatsu Motor president

    Masahiro Inoue (R), head of Toyota Motor Corp.'s operations in the Latin America and Caribbean region, attends a press conference in Tokyo on Feb. 13, 2024, after being appointed as Daihatsu Motor Co.'s new president. Toyota President Koji Sato is seen on the left.
      Rakuten, Japan Post in capital tie-up

      Rakuten, Japan Post in capital tie-up

      Japanese e-commerce giant Rakuten Inc. Chairman and CEO Hiroshi Mikitani (L) and Japan Post Holdings Co. President and CEO Hiroya Masuda hold a joint press conference in Tokyo on March 12, 2021. The two companies said the same day Rakuten will sell an 8.32 percent stake to Japan Post for about 150 billion yen ($1.38 billion).
        Rakuten, Japan Post in capital tie-up

        Rakuten, Japan Post in capital tie-up

        Japanese e-commerce giant Rakuten Inc. Chairman and CEO Hiroshi Mikitani (L) and Japan Post Holdings Co. President and CEO Hiroya Masuda hold a joint press conference in Tokyo on March 12, 2021. The two companies said the same day Rakuten will sell an 8.32 percent stake to Japan Post for about 150 billion yen ($1.38 billion).
          Rakuten, Japan Post in capital tie-up

          Rakuten, Japan Post in capital tie-up

          Japanese e-commerce giant Rakuten Inc. Chairman and CEO Hiroshi Mikitani (L) and Japan Post Holdings Co. President and CEO Hiroya Masuda fist bump through a transparent acrylic board at a press conference in Tokyo on March 12, 2021, amid the novel coronavirus pandemic. The two companies said the same day Rakuten will sell an 8.32 percent stake to Japan Post for about 150 billion yen ($1.38 billion).
            NTT's stake in NTT Docomo to rise to 91% in successful tender offer

            NTT's stake in NTT Docomo to rise to 91% in successful tender offer

            Nippon Telegraph and Telephone Corp. President Jun Sawada makes a speech in Tokyo on Nov. 17. 2020. NTT's shareholding in its mobile phone subsidiary NTT Docomo Inc. will rise to 91.46 percent from 66.21 percent as a result of its successful tender offer.
              Yahoo Japan and messaging app Line to merge

              Yahoo Japan and messaging app Line to merge

              Kentaro Kawabe (L), president of SoftBank Corp. subsidiary Z Holdings Corp., and Takashi Idezawa, president of messaging app provider Line Corp., shake hands in Tokyo on Nov. 18, 2019, after announcing a merger between Yahoo Japan Corp., held by Z Holdings, and Line by October 2020. (Kyodo) ==Kyodo
                Mitsubishi Chemical HD to make Mitsubishi Tanabe Pharma Corporation a wholly owned subsidiary

                Mitsubishi Chemical HD to make Mitsubishi Tanabe Pharma Corporation a wholly owned subsidiary

                Mitsubishi Chemical Holdings (HD) announced on the 18th that it will invest up to 491.8 billion yen to make its consolidated subsidiary Mitsubishi Tanabe Pharma Corporation a wholly owned subsidiary. Currently, MCHC holds 56.39% of Mitsubishi Tanabe Pharma's shares, and will conduct a tender offer from January 19 to January 7, 2020, aiming to make Mitsubishi Tanabe Pharma its wholly owned subsidiary. At a press conference in Tokyo on January 18, MCHC President Hitoshi Ochi said, "The world is evolving greatly and healthcare is developing at a very fast pace. Mitsubishi Tanabe Pharma will also accelerate the overseas development of promising new drug candidates by using MCHC's human resources. The company will utilize the diverse resources of a comprehensive chemical manufacturer to efficiently create new businesses and enhance the earnings structure of a core healthcare company. (November 18, 2019, Tokyo, Japan; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                  Otsuka to buy U.S. biopharmaceutical firm Avanir for $3.5 bil.

                  Otsuka to buy U.S. biopharmaceutical firm Avanir for $3.5 bil.

                  TOKYO, Japan - Tatsuo Higuchi, president of Otsuka Holdings Co., attends a press conference in Tokyo's Minato Ward on Dec. 2, 2014, on the planned acquisition by its subsidiary Otsuka Pharmaceutical Co. of California-based biopharmaceutical firm Avanir Pharmaceuticals Inc. for $3.54 billion through a tender offer to be followed by a merger. The Japanese nutrition product and drug manufacturer will pay $17 per Avanir share in the takeover bid through its U.S. subsidiary.
                    Toray agrees on 1 tril. yen supply contract with Boeing

                    Toray agrees on 1 tril. yen supply contract with Boeing

                    TOKYO, Japan - Akihiro Nikkaku (L), president of Toray Industries Inc., shakes hands with John J. Tracy, chief technology officer of Boeing Co., at a press conference in Tokyo on Nov. 17, 2014. Toray said it has agreed on a new contract worth 1 trillion yen (about $8.7 billion) to supply carbon fiber for Boeing's jets and will begin talks to work together with the U.S. aircraft maker to lower the costs of the lightweight material. (Kyodo)
                      Avigan could be formally approved as Ebola drug early 2015

                      Avigan could be formally approved as Ebola drug early 2015

                      TOKYO, Japan - Shigetaka Komori, chief executive officer of Fujifilm Holdings Corp., attends a press conference in Tokyo, Japan, on Nov. 11, 2014, announcing that the company expects its Avigan anti-influenza drug to be formally approved early next year for treating people infected with the Ebola virus. (Kyodo)